VOS Healthcare is a leading provider of stem cell therapy and regenerative medicine services globally. It has a large, loyal customer base and aims to converge all stem cell-related services. VOS sees significant growth opportunities through expansion, cross-selling, and leveraging its innovative technologies and global infrastructure. It has achieved strong and consistent financial performance with high recurring revenue streams.
VOS Healthcare is positioned to become a leading global player in stem cell therapy and banking. It has established operations across multiple countries with a goal of providing seamless stem cell collection, processing, storage and treatment services worldwide. VOS generates over 75% of its revenue from recurring sources like cord blood and menstrual blood banking through a large, loyal customer base. Its experienced team and quality operations provide a strong foundation for continued growth and leadership in the regenerative medicine industry.
VOS Healthcare is a leading provider of stem cell therapy and banking services globally. It has achieved strong and consistent financial growth in recent years through recurring revenue streams that account for over 75% of its revenues. VOS aims to leverage its large customer base and global presence to further expand its leadership position in the stem cell therapy market, which remains highly fragmented.
Hemas Holdings PLC reported strong financial results for the first half of 2012/13, with group turnover increasing 29% and PAT growing 46% compared to the same period last year. Key drivers of growth were the power, healthcare, and FMCG sectors. The company's consumer businesses, including FMCG, healthcare, and leisure, contributed over 80% of total revenue. Earnings growth boosted ROE to 13.6% for the period.
Hemas Holdings PLC is a diversified conglomerate in Sri Lanka that saw growth in revenue and earnings in Q3 2012/13. Key points:
- Group revenue increased 26% year-over-year to LKR 19.2 billion, driven by the power, healthcare, and FMCG sectors.
- Net profit grew 30% to LKR 1.2 billion. The FMCG, leisure, healthcare, and transportation sectors contributed strongly to earnings growth.
- Several subsidiaries and business lines performed well, with the pharmaceutical, hotel, and aviation businesses seeing particularly strong growth.
- CSR initiatives included opening new preschools and constructing a model school in Kilinochchi
The Korea Fund underperformed the MSCI Korea benchmark in the second quarter of 2012, with the MSCI Korea dropping sharply by 8.6% in USD terms. Foreign investors sold a net $5 trillion worth of Korean equities, though the Korean won depreciated only moderately against the USD. During the quarter, the Fund outperformed its benchmark by 42 basis points due to strong stock picks in consumer discretionary, while IT and materials detracted. Quality stocks outperformed in the volatile market conditions, with low debt, low volatility stocks performing well.
One of India's oldest banks, Canara Bank has over 100 years of operations. It is among the top 10 banks in India in terms of asset size and is majority owned by the Government of India. Canara Bank has a strong branch network across India and focuses on priority sectors like agriculture and small businesses. It has demonstrated strong financial performance in recent years through measures like repricing deposits to boost income and lowering costs. Analysts project continued growth in profits for Canara Bank on the back of rising interest income and improving margins. The report recommends buying Canara Bank shares with a target price of Rs. 899 based on projected book value multiples.
Private Equity In Mena Tadhamon Research Note April 2011Junaid Jafar
Private equity activity in the MENA region declined in 2010. Fundraising fell 58% to $448 million while the value of deals increased 67% to $1.07 billion, driven mainly by investments in the UAE. Top sectors were information technology, healthcare, and financial services. However, private equity in the region faces challenges including difficulty raising capital for smaller funds, limited openness of family-owned businesses to outside investment, and lack of experienced professionals and transparency.
VOS Healthcare is positioned to become a leading global player in stem cell therapy and banking. It has established operations across multiple countries with a goal of providing seamless stem cell collection, processing, storage and treatment services worldwide. VOS generates over 75% of its revenue from recurring sources like cord blood and menstrual blood banking through a large, loyal customer base. Its experienced team and quality operations provide a strong foundation for continued growth and leadership in the regenerative medicine industry.
VOS Healthcare is a leading provider of stem cell therapy and banking services globally. It has achieved strong and consistent financial growth in recent years through recurring revenue streams that account for over 75% of its revenues. VOS aims to leverage its large customer base and global presence to further expand its leadership position in the stem cell therapy market, which remains highly fragmented.
Hemas Holdings PLC reported strong financial results for the first half of 2012/13, with group turnover increasing 29% and PAT growing 46% compared to the same period last year. Key drivers of growth were the power, healthcare, and FMCG sectors. The company's consumer businesses, including FMCG, healthcare, and leisure, contributed over 80% of total revenue. Earnings growth boosted ROE to 13.6% for the period.
Hemas Holdings PLC is a diversified conglomerate in Sri Lanka that saw growth in revenue and earnings in Q3 2012/13. Key points:
- Group revenue increased 26% year-over-year to LKR 19.2 billion, driven by the power, healthcare, and FMCG sectors.
- Net profit grew 30% to LKR 1.2 billion. The FMCG, leisure, healthcare, and transportation sectors contributed strongly to earnings growth.
- Several subsidiaries and business lines performed well, with the pharmaceutical, hotel, and aviation businesses seeing particularly strong growth.
- CSR initiatives included opening new preschools and constructing a model school in Kilinochchi
The Korea Fund underperformed the MSCI Korea benchmark in the second quarter of 2012, with the MSCI Korea dropping sharply by 8.6% in USD terms. Foreign investors sold a net $5 trillion worth of Korean equities, though the Korean won depreciated only moderately against the USD. During the quarter, the Fund outperformed its benchmark by 42 basis points due to strong stock picks in consumer discretionary, while IT and materials detracted. Quality stocks outperformed in the volatile market conditions, with low debt, low volatility stocks performing well.
One of India's oldest banks, Canara Bank has over 100 years of operations. It is among the top 10 banks in India in terms of asset size and is majority owned by the Government of India. Canara Bank has a strong branch network across India and focuses on priority sectors like agriculture and small businesses. It has demonstrated strong financial performance in recent years through measures like repricing deposits to boost income and lowering costs. Analysts project continued growth in profits for Canara Bank on the back of rising interest income and improving margins. The report recommends buying Canara Bank shares with a target price of Rs. 899 based on projected book value multiples.
Private Equity In Mena Tadhamon Research Note April 2011Junaid Jafar
Private equity activity in the MENA region declined in 2010. Fundraising fell 58% to $448 million while the value of deals increased 67% to $1.07 billion, driven mainly by investments in the UAE. Top sectors were information technology, healthcare, and financial services. However, private equity in the region faces challenges including difficulty raising capital for smaller funds, limited openness of family-owned businesses to outside investment, and lack of experienced professionals and transparency.
Presentazione delle funzionalità dell' APP all'Ordine dei Dottori Commercialisti ed Esperti Contabili di Tortona .
Le funzionalità attualmente disponibili sono:
Formazione accreditata: Vengono pubblicati i corsi di formazione organizzati ed accreditati, ad ogni inserimento si riceve una notifica automatica ed è possibile iscriversi direttamente dall'app all'evento formativo
Comunicazioni Ordine: Vengono pubblicate le comunicazioni dell'ordine professionale di appartenenza ( per gli ordini aderenti)
Offerte: Offerte dedicate agli utilizzatori dell'app inserite dagli sponsor di ITincontra inerenti gli strumenti utilizzati per lo svolgimento della professione.
L’evoluzione digitale migliorata e potenziata dei classici strumenti per gli appunti. Evernote: un potentissimo programma utilizzabile su qualsiasi dispositivo sempre sincronizzato e al 100% gratuito
Flurry Mobile App Industry Trends Presentation, Business Insider Mobile Adver...Flurry, Inc.
This presentation covers key insights across the mobile app economy including market size, addressable market, consumer trends, what non-mobile industries and categories are being disrupted by mobile apps, comparison of consumer behavior on media platforms vs. ad spending and an outlook for what's next as the industry matures.
Makeitapp - Presentazione app mobile & suite proximity marketing per centri c...Makeitapp
Presentazione dedicata alle funzionalità dell’applicazione mobile e alla piattaforma di proximity marketing studiate per gallerie e centri commerciali.
La presentazione mostra inoltre un case history di successo: l’applicazione mobile corredata di suite di Proximity Marketing realizzata per Orio Center, lo Shopping Center più famoso d'Italia, a due passi dall'aeroporto internazionale di Orio al Serio.
L’applicazione mostra i 200 negozi del centro, tutte le novità e promozioni, tutti gli imperdibili eventi e le informazioni utili sul centro.
Gli utenti che hanno scaricato l’applicazione, quando si trovano all’interno del centro commerciale, potranno ricevere notizie e promozioni contestuali rispetto alla loro esatta posizione grazie alla tecnologia beacon.
presentazione usata da Massimiliano Atzori, Andrea Di Benedetto e Eleonora Borelli nel loro intervento a "Cultura, Agricoltura e Territorio. Le leve per lo sviluppo toscano", San Casciano, 6 febbraio 2014
Piano di Marketing per Benetton. Ideazione nuova collezione dedicata a un target più giovane e attento alle tendenze. Realizzato per il corso IED, primo anno.
sviluppa la tua app con ofunwebservices. i siti web ormai sono congestionati. web marketing legato a logiche seo non sempre porta i frutti sperati. il mercato mobile è un mercato che, a livello di app aziendali, non è ancora completamente esplorato e quindi può portare originalità e aria nuova al tuo brand.
In this update of his past presentations on Mobile Eating the World -- delivered most recently at The Guardian's Changing Media Summit -- a16z’s Benedict Evans takes us through how technology is universal through mobile. How mobile is not a subset of the internet anymore. And how mobile (and accompanying trends of cloud and AI) is also driving new productivity tools.
In fact, mobile -- which encompasses everything from drones to cars -- is everything.
This annual report summarizes Quest Diagnostics' financial and operational performance in 2006. Key points include:
- Net revenues grew 15% to $6.3 billion while earnings per share grew 13% to $3.14.
- The company enhanced its value to patients, physicians, and payers while reporting strong financial results.
- Quest Diagnostics remains committed to improving the patient experience, driving growth, and supporting its employees despite challenges in a consolidating healthcare sector with increasing pricing pressure.
This annual report summarizes BD's financial and operational performance in fiscal year 2007. Key points:
- Revenues increased 11% to $6.36 billion due to strong sales growth across all business segments. Net income increased 5% to $856 million.
- All business segments - BD Medical, BD Diagnostics, and BD Biosciences - experienced solid revenue growth between 10-13% driven by new product innovations and acquisitions.
- BD remains committed to returning cash to shareholders, spending $690 million in fiscal 2007 on share repurchases and dividends.
- The report highlights BD's focus on innovation through increased R&D spending and strategic acquisitions in areas like healthcare
This annual report summarizes BD's financial and operational performance in fiscal year 2007. Key points:
- Revenues increased 11% to $6.36 billion due to strong sales growth across all business segments. Net income increased 5% to $856 million.
- All business segments - BD Medical, BD Diagnostics, and BD Biosciences - experienced solid revenue growth between 10-13% driven by new product innovations and acquisitions.
- BD remains committed to returning cash to shareholders, spending $690 million in fiscal 2007 on share repurchases and dividends.
- The report highlights BD's focus on innovation through increased R&D spending and strategic acquisitions in areas like healthcare
This annual report summarizes BD's financial and operational performance in fiscal year 2007. Key points:
- Revenues increased 11% to $6.36 billion due to strong sales growth across all business segments. Net income increased 5% to $856 million.
- All business segments - BD Medical, BD Diagnostics, and BD Biosciences - experienced solid revenue growth between 10-13% driven by new product innovations and acquisitions.
- BD remains committed to returning cash to shareholders, spending $690 million (over 56% of operating cash flow) on share repurchases and dividends. The dividend was increased by 16% to $1.14 per share.
- The report
This annual report summarizes BD's financial and operational performance in fiscal year 2007. Key points:
- Revenues increased 11% to $6.36 billion due to strong sales growth across all business segments. Net income increased 5% to $856 million.
- All business segments - BD Medical, BD Diagnostics, and BD Biosciences - experienced solid revenue growth between 10-13% driven by new product innovations and acquisitions.
- BD remains committed to returning cash to shareholders, spending $690 million (over 56% of operating cash flow) on share repurchases and dividends. The dividend was increased by 16% to $1.14 per share.
- The report
Capital structure decisions and profitabilitybappykazi
Group G is analyzing the capital structure and profitability of Square Pharmaceuticals Ltd. The group members are Kazi Tanvirul Islam, S.M. Zayed Siraj, Jannatul Ferdows, Md. Tajmilur Rahman, and Umma Kulsum. Square Pharmaceuticals gets financing from equity, debt, retained earnings and borrowed funds. Its average debt ratio from 2006-2010 was 29% and debt increased 20% while equity increased 80%. Square Pharmaceuticals maintains low debt levels and has sound financial performance with average debt-equity ratio of 0.4. The company has stable profit margins around 18% on average.
Tenet Healthcare Corporation owns and operates general hospitals and related healthcare services across the US. In fiscal year 2001, Tenet achieved strong financial and operating results including a 27.1% increase in earnings per share and a 32.3% increase in net income from operations. They reduced debt by $1.45 billion. Tenet's Target 100 initiative, designed for 100% patient, physician, and employee satisfaction, has led to culture change and measurable improvements in patient satisfaction scores and admissions growth at their hospitals.
Safeguard Scientifics is a publicly traded holding company that provides capital and expertise to help entrepreneurs accelerate growth and build value in healthcare and technology companies. It has successfully invested in and supported over 200 companies since 1953. Safeguard focuses on partner companies with high growth potential and strong competitive positions. Its current partner companies have a combined revenue run rate of over $500 million and represent over $150 million in capital deployed across healthcare and technology sectors. Safeguard aims to continue supporting partner company growth, realizing successful exits, and returning excess cash to shareholders in 2015.
- Johnson & Johnson is a global healthcare company comprised of over 250 companies working to improve health and well-being worldwide.
- In 2007, the company achieved record sales of $61.1 billion and introduced hundreds of new products across its pharmaceutical, medical device, and consumer health divisions.
- The acquisition of Pfizer Consumer Healthcare expanded Johnson & Johnson's global consumer health leadership, and integration of the business is proceeding ahead of schedule.
Presentazione delle funzionalità dell' APP all'Ordine dei Dottori Commercialisti ed Esperti Contabili di Tortona .
Le funzionalità attualmente disponibili sono:
Formazione accreditata: Vengono pubblicati i corsi di formazione organizzati ed accreditati, ad ogni inserimento si riceve una notifica automatica ed è possibile iscriversi direttamente dall'app all'evento formativo
Comunicazioni Ordine: Vengono pubblicate le comunicazioni dell'ordine professionale di appartenenza ( per gli ordini aderenti)
Offerte: Offerte dedicate agli utilizzatori dell'app inserite dagli sponsor di ITincontra inerenti gli strumenti utilizzati per lo svolgimento della professione.
L’evoluzione digitale migliorata e potenziata dei classici strumenti per gli appunti. Evernote: un potentissimo programma utilizzabile su qualsiasi dispositivo sempre sincronizzato e al 100% gratuito
Flurry Mobile App Industry Trends Presentation, Business Insider Mobile Adver...Flurry, Inc.
This presentation covers key insights across the mobile app economy including market size, addressable market, consumer trends, what non-mobile industries and categories are being disrupted by mobile apps, comparison of consumer behavior on media platforms vs. ad spending and an outlook for what's next as the industry matures.
Makeitapp - Presentazione app mobile & suite proximity marketing per centri c...Makeitapp
Presentazione dedicata alle funzionalità dell’applicazione mobile e alla piattaforma di proximity marketing studiate per gallerie e centri commerciali.
La presentazione mostra inoltre un case history di successo: l’applicazione mobile corredata di suite di Proximity Marketing realizzata per Orio Center, lo Shopping Center più famoso d'Italia, a due passi dall'aeroporto internazionale di Orio al Serio.
L’applicazione mostra i 200 negozi del centro, tutte le novità e promozioni, tutti gli imperdibili eventi e le informazioni utili sul centro.
Gli utenti che hanno scaricato l’applicazione, quando si trovano all’interno del centro commerciale, potranno ricevere notizie e promozioni contestuali rispetto alla loro esatta posizione grazie alla tecnologia beacon.
presentazione usata da Massimiliano Atzori, Andrea Di Benedetto e Eleonora Borelli nel loro intervento a "Cultura, Agricoltura e Territorio. Le leve per lo sviluppo toscano", San Casciano, 6 febbraio 2014
Piano di Marketing per Benetton. Ideazione nuova collezione dedicata a un target più giovane e attento alle tendenze. Realizzato per il corso IED, primo anno.
sviluppa la tua app con ofunwebservices. i siti web ormai sono congestionati. web marketing legato a logiche seo non sempre porta i frutti sperati. il mercato mobile è un mercato che, a livello di app aziendali, non è ancora completamente esplorato e quindi può portare originalità e aria nuova al tuo brand.
In this update of his past presentations on Mobile Eating the World -- delivered most recently at The Guardian's Changing Media Summit -- a16z’s Benedict Evans takes us through how technology is universal through mobile. How mobile is not a subset of the internet anymore. And how mobile (and accompanying trends of cloud and AI) is also driving new productivity tools.
In fact, mobile -- which encompasses everything from drones to cars -- is everything.
This annual report summarizes Quest Diagnostics' financial and operational performance in 2006. Key points include:
- Net revenues grew 15% to $6.3 billion while earnings per share grew 13% to $3.14.
- The company enhanced its value to patients, physicians, and payers while reporting strong financial results.
- Quest Diagnostics remains committed to improving the patient experience, driving growth, and supporting its employees despite challenges in a consolidating healthcare sector with increasing pricing pressure.
This annual report summarizes BD's financial and operational performance in fiscal year 2007. Key points:
- Revenues increased 11% to $6.36 billion due to strong sales growth across all business segments. Net income increased 5% to $856 million.
- All business segments - BD Medical, BD Diagnostics, and BD Biosciences - experienced solid revenue growth between 10-13% driven by new product innovations and acquisitions.
- BD remains committed to returning cash to shareholders, spending $690 million in fiscal 2007 on share repurchases and dividends.
- The report highlights BD's focus on innovation through increased R&D spending and strategic acquisitions in areas like healthcare
This annual report summarizes BD's financial and operational performance in fiscal year 2007. Key points:
- Revenues increased 11% to $6.36 billion due to strong sales growth across all business segments. Net income increased 5% to $856 million.
- All business segments - BD Medical, BD Diagnostics, and BD Biosciences - experienced solid revenue growth between 10-13% driven by new product innovations and acquisitions.
- BD remains committed to returning cash to shareholders, spending $690 million in fiscal 2007 on share repurchases and dividends.
- The report highlights BD's focus on innovation through increased R&D spending and strategic acquisitions in areas like healthcare
This annual report summarizes BD's financial and operational performance in fiscal year 2007. Key points:
- Revenues increased 11% to $6.36 billion due to strong sales growth across all business segments. Net income increased 5% to $856 million.
- All business segments - BD Medical, BD Diagnostics, and BD Biosciences - experienced solid revenue growth between 10-13% driven by new product innovations and acquisitions.
- BD remains committed to returning cash to shareholders, spending $690 million (over 56% of operating cash flow) on share repurchases and dividends. The dividend was increased by 16% to $1.14 per share.
- The report
This annual report summarizes BD's financial and operational performance in fiscal year 2007. Key points:
- Revenues increased 11% to $6.36 billion due to strong sales growth across all business segments. Net income increased 5% to $856 million.
- All business segments - BD Medical, BD Diagnostics, and BD Biosciences - experienced solid revenue growth between 10-13% driven by new product innovations and acquisitions.
- BD remains committed to returning cash to shareholders, spending $690 million (over 56% of operating cash flow) on share repurchases and dividends. The dividend was increased by 16% to $1.14 per share.
- The report
Capital structure decisions and profitabilitybappykazi
Group G is analyzing the capital structure and profitability of Square Pharmaceuticals Ltd. The group members are Kazi Tanvirul Islam, S.M. Zayed Siraj, Jannatul Ferdows, Md. Tajmilur Rahman, and Umma Kulsum. Square Pharmaceuticals gets financing from equity, debt, retained earnings and borrowed funds. Its average debt ratio from 2006-2010 was 29% and debt increased 20% while equity increased 80%. Square Pharmaceuticals maintains low debt levels and has sound financial performance with average debt-equity ratio of 0.4. The company has stable profit margins around 18% on average.
Tenet Healthcare Corporation owns and operates general hospitals and related healthcare services across the US. In fiscal year 2001, Tenet achieved strong financial and operating results including a 27.1% increase in earnings per share and a 32.3% increase in net income from operations. They reduced debt by $1.45 billion. Tenet's Target 100 initiative, designed for 100% patient, physician, and employee satisfaction, has led to culture change and measurable improvements in patient satisfaction scores and admissions growth at their hospitals.
Safeguard Scientifics is a publicly traded holding company that provides capital and expertise to help entrepreneurs accelerate growth and build value in healthcare and technology companies. It has successfully invested in and supported over 200 companies since 1953. Safeguard focuses on partner companies with high growth potential and strong competitive positions. Its current partner companies have a combined revenue run rate of over $500 million and represent over $150 million in capital deployed across healthcare and technology sectors. Safeguard aims to continue supporting partner company growth, realizing successful exits, and returning excess cash to shareholders in 2015.
- Johnson & Johnson is a global healthcare company comprised of over 250 companies working to improve health and well-being worldwide.
- In 2007, the company achieved record sales of $61.1 billion and introduced hundreds of new products across its pharmaceutical, medical device, and consumer health divisions.
- The acquisition of Pfizer Consumer Healthcare expanded Johnson & Johnson's global consumer health leadership, and integration of the business is proceeding ahead of schedule.
This document is the 2003 annual report for Quest Diagnostics. It discusses the company's financial performance in 2003, highlighting record earnings per share growth of 28% and revenues growth of 15%. It outlines the company's strategic focus on six sigma quality, access and convenience, innovative science and medicine, and advanced information technology. The report provides examples of new diagnostic tests introduced in 2003 to improve disease diagnosis and treatment.
The document is Aetna's 2005 annual report. It summarizes that 2005 was a successful year for Aetna with 13% revenue growth to $22.5 billion. Medical membership increased by over 1 million members which was primarily organic growth. Aetna also saw strong growth in dental and pharmacy membership. The company managed a commercial risk medical cost trend of over 8% while maintaining one of the best medical cost ratios in the industry at 78.4%, excluding prior period reserve development.
Capital Group Holdings operates 7 urgent care clinics in Phoenix and will launch a telemedicine service called OneHealthPass. The company seeks to provide immediate access to medical services to avoid delays and reduce healthcare costs. It plans to continue acquiring urgent care clinics across the US and ensuring telehealth patients can visit clinics if needed. Recent events include acquiring Alliance Urgent Care and developing integrated marketing for the clinics and telehealth service.
Valeant provided an update on its Q4 2014 operational highlights and guidance. It reported strong organic growth across most business units, with total company organic growth expected to be over 12% for Q4 and over 10% for the full year. It also made progress on its R&D pipeline and completed several business development deals. Valeant maintained its revenue guidance of $2.1-2.3 billion for Q4 but raised its cash EPS guidance to over $2.55 and reiterated its adjusted cash flow from operations guidance of approximately $600 million.
The document analyzes the 2013 financial performance of the Big Four accounting firms - Deloitte, EY, KPMG, and PwC. It finds that the firms had moderate 3.2% revenue growth in 2013 to a record $114 billion, below expectations, with variation across service lines and regions. Audit revenues were flat while Asia declined 1.3%. Deloitte had the fastest growth at 3.5% and surpassed PwC to regain its position as the largest firm. EY grew the most at 5.8% while KPMG grew just 1.7%. The Americas became the top region, growing 6.8% while Europe grew 1.4% and Asia declined
Why Own Safeguard?
- Full Value Yet to be Realized
- Ownership Stakes in Exciting Partner Companies
- Top Performance of Proven Team
- Financial Strength, Flexibility and Liquidity
- Strong Alignment of Interests
Forward-Looking Statements
Statements contained in this presentation that are not historical facts are forward looking statements which involve certain risks and uncertainties including, but not limited to, risks associated with the uncertainty of managing rapidly changing technologies, limited access to capital, competition, the ability to attract and retain qualified employees, our ability to execute our strategy, the uncertainty of the future performance of our partner companies, acquisitions and dispositions of additional partner companies, the inability to manage growth, government regulation and legal liabilities and the effect of economic conditions in the business sectors in which our partner companies operate, negative media coverage and other uncertainties as described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Safeguard does not assume any obligation to update any forward looking statements or other information contained in this presentation.
Cover SheetProject Analysis ByMatthew PankeyBBA in Finance2011-20MerrileeDelvalle969
Cover SheetProject Analysis By:Matthew PankeyBBA in Finance2011-2021MGT 4810 W1-W2 Fall 2022
Executive SummaryExecutive Summary Johnson & Johnson is a multinational American company with headquarters in New Bunswick, New Jersey. Medical devices, pharmaceuticals, and consumer health are the three main business sectors of Johnson & Johnson, which was founded in 1886. J&J is a Fortune 500 firm with about 250 subsidiary businesses that operate in more than 60 countries and sell goods in more than 175 nations. To stand out from rivals, Johnson & Johnson relies on its products and innovation. With the help of this company analysis, students can examine every facet of Johnson & Johnson's operations as consultants. This pertinent data may be used to shed light on how J&J might enhance internal and external operations while enhancing its financial performance and stockholder value. The Strategic Management textbook and other trustworthy sources, such as Johnson & Johnson's annual reports, investor website, and news releases, were used to compile all of the information for this research. Through this capstone project, students can examine pertinent corporate finances and gain knowledge about the potential pitfalls of their chosen career pathways.I was able to get substantial Microsoft Excel knowledge with this assignment, which will help me as I begin to improve my career-related skills. Due to the significant study and analysis required to create each tool, I also had to learn good time management techniques. When examining a company's financials and annual reports to estimate its value, I also feel as though I learned knowledge.
Table of ContentsTable of ContentsTool 1:Historical AnalysisPage 4Tool 2:Mission Statement AnalysisPage 5Tool 3:Remote Environment AnalysisPage 7Tool 4:Competitive Profile MatrixPage 12Tool 5:Internal Factor EvaluationPage 14Tool 6:CohesionPage 17Tool 7:Generic StrategyPage 20Tool 8:Perceptual MappingPage 22Tool 9:GlobalizationPage 23Tool 10:Financial Ratios and BenchmarkingPage 25Tool 11:SWOTPage 30Tool 12:Financing Recommendations for SWOTPage 35
Tool 1Historical AnalysisPurpose: Identify which strategies have historically been successful and how they have affected revenue by relating recent strategic events inside the company to consumer health, medicines, medical devices, and overall revenues. Findings from this research will be used in a SWOT analysis to identify strengths and weaknesses. Data was taken from yearly reports by Johnson & Johnson.YearsGross RevenueConsumer HealthPharmaceuticalMedical Devices2011$82,584$14,053$45,572$22,9592012$82,059$13,898$42,198$25,9632013$81,581$13,853$40,734$26,9942014$76,450$13,602$36,256$26,5922015$71,890$13,307$33,464$25,1192016$70,074$13,507$31,430$25,1372017$74,331$14,496$32,313$27,5222018$71,312$14,697$28,125$28,4902019$67,224$14,447$25,351$27,4262020$65,030$14,883$24,368$25,7792021$93,775$14,635$52,080$27,060Recent Strategic Events2, 3March 2011: Acquires Crucell, a biopharmac ...
This annual report summarizes BD's performance in 2004. Key points include:
- Revenues grew 10.6% to $4.934 billion, income from continuing operations grew 5% to $582.5 million, and diluted EPS grew 5.2% to $2.21.
- Each of BD's three business segments (Medical, Diagnostics, Biosciences) contributed to revenue growth.
- BD achieved strong operational performance through initiatives in lean manufacturing, inventory management, and customer service.
- BD launched several new products that drove revenue growth and furthered its mission of innovating for impact in healthcare.
This document contains the prepared remarks from Quest Diagnostics' third quarter 2006 conference call. [1] It discusses Quest's strong financial results for Q3 2006, including 16% revenue growth and 21% earnings growth. [2] It provides details on revenue, volume, and margin performance. [3] It also addresses Quest's ongoing contract dispute with UnitedHealthcare and Quest's strategies for retaining United business and continuing to drive growth organically and through acquisitions.
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
Summary: Even in a time of high biopharma valuations, adopting an activist mentality adds rigor to capital allocation and strategic decision-making, improving not just returns to shareholders but long-term value creation. Therefore, biopharma management teams and boards of directors should proactively assess the “fitness” of their capital allocation strategies and their alignment with operational performance goals by taking an outsider’s view of the business even when times are good — and before a material stumble provides a compelling reason for an outsider to act. For more on this topic, go to http://www.ey.com/GL/en/Industries/Life-Sciences/EY-vital-signs-how-fit-is-your-capital-allocation-strategy.
Starting a business is like embarking on an unpredictable adventure. It’s a journey filled with highs and lows, victories and defeats. But what if I told you that those setbacks and failures could be the very stepping stones that lead you to fortune? Let’s explore how resilience, adaptability, and strategic thinking can transform adversity into opportunity.
Industrial Tech SW: Category Renewal and CreationChristian Dahlen
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
Best Competitive Marble Pricing in Dubai - ☎ 9928909666Stone Art Hub
Stone Art Hub offers the best competitive Marble Pricing in Dubai, ensuring affordability without compromising quality. With a wide range of exquisite marble options to choose from, you can enhance your spaces with elegance and sophistication. For inquiries or orders, contact us at ☎ 9928909666. Experience luxury at unbeatable prices.
𝐔𝐧𝐯𝐞𝐢𝐥 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐄𝐧𝐞𝐫𝐠𝐲 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐰𝐢𝐭𝐡 𝐍𝐄𝐖𝐍𝐓𝐈𝐃𝐄’𝐬 𝐋𝐚𝐭𝐞𝐬𝐭 𝐎𝐟𝐟𝐞𝐫𝐢𝐧𝐠𝐬
Explore the details in our newly released product manual, which showcases NEWNTIDE's advanced heat pump technologies. Delve into our energy-efficient and eco-friendly solutions tailored for diverse global markets.
AI Transformation Playbook: Thinking AI-First for Your BusinessArijit Dutta
I dive into how businesses can stay competitive by integrating AI into their core processes. From identifying the right approach to building collaborative teams and recognizing common pitfalls, this guide has got you covered. AI transformation is a journey, and this playbook is here to help you navigate it successfully.
Part 2 Deep Dive: Navigating the 2024 Slowdownjeffkluth1
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...APCO
The Radar reflects input from APCO’s teams located around the world. It distils a host of interconnected events and trends into insights to inform operational and strategic decisions. Issues covered in this edition include:
The Steadfast and Reliable Bull: Taurus Zodiac Signmy Pandit
Explore the steadfast and reliable nature of the Taurus Zodiac Sign. Discover the personality traits, key dates, and horoscope insights that define the determined and practical Taurus, and learn how their grounded nature makes them the anchor of the zodiac.
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
Profiles of Iconic Fashion Personalities.pdfTTop Threads
The fashion industry is dynamic and ever-changing, continuously sculpted by trailblazing visionaries who challenge norms and redefine beauty. This document delves into the profiles of some of the most iconic fashion personalities whose impact has left a lasting impression on the industry. From timeless designers to modern-day influencers, each individual has uniquely woven their thread into the rich fabric of fashion history, contributing to its ongoing evolution.
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...BBPMedia1
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS
2. Disclaimer
This Investor Presentation has been prepared by VOS HEALTHCARE LLC, USA . For investors, solely for informational
purposes.
The information contained herein has been prepared to assist prospective investors in making their own evaluation of the Company and does no
purport to be all-inclusive or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should
conduct their own investigation and analysis of the Company and the data set forth in this information. VOS makes no representation or warran
the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding informa
contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of
evaluation of the Company.
This Information includes certain statements and estimates provided by the Company with respect to the projected future performance of the
Company. Such statements, estimates and projections reflect various assumptions by management concerning possible anticipated results, whi
assumptions may or may not be correct. No representations are made as to the accuracy of such statements, estimates or projections. Prospec
investors will be expected to have conducted their own due diligence investigation regarding these and all other matters pertinent to investment
Company.
This presentation may contain statements that are not historical facts, referred to as “forward looking statements.” The corporation’s actual futur
results may differ materially from those suggested by such statements, depending on various factors including those described in filings made w
SEC.
2
4. Mission
NaSCFI goal is to be the largest STEM CELL THERAPY AND BANKING services player in the world.
CONVERGENCE
The company’s technology vision is to focus on convergence of all STEM CELL THERAPY and STEM CELL BANKING in a manner that
Patient can seamlessly get treatment or services at door step. . The company intends to do that by designing products and services that
are pioneering and at least a few years ahead of its competition. The company believes that profitability and revenue growth must go hand
in hand.
With no competitors who can match the completeness of its vision or its distinct advantages, NaSCFI is ideally positioned to seize an
enormous “green field” opportunity. Continually cited for the high quality of its offering, NaSCFI has built an outstanding reputation among
a large, impressive customer base. With a strong recurring, Stem Cell therapy as a Therapeutic Cure model, NaSCFI is positioned to be a
leading player in the Healthcare, surely moving towards the disease free world
4
5. VOS HEALTHCARE Introduction
VOS Healthcare Pvt Ltd (the “Company”) was founded in 2011 by VOS Healthcare LLC, USA, a Washington corporation.
VOS Healthcare LLC, USA is a leading provider of Adult Stem cell therapy and Regenerative medicine and Stem Cell Banking
( Cord Blood and Menstrual blood banking). VOS provides therapeutic as well as storing facilities all over the globe. Our
services are ranging from collection, transportation, carrier systems, sterile environment for packaging, laboratory and
centers, Banking of Stem cell along with a solutions storing for variety of period and flexibility of payment all across the globe.
VOS powers multiple exchanges across the world in the field of Autologous Stem cell Production, Differentiations, Newer
research Treatment and Research in Biopharma conducting in excess of $100 billion at the possible sector of business on its
platforms
VOS’s goal is to be the leading backend powerhouse of STEM CELL THERAPY in the world. The Company’s healthcare vision is to
focus on convergence of all possible therapies in Stem cell, processes of Stem Cell Banking, Culturing and Differentiation of the
stem cell, Derivation and Perpetuating in to Tissue Specific Cell, Cell cytometeric counting, Sterile chain and delivery to the
patient all these in a manner such that viability and sterility is maintained and the complete complex function can seamlessly
flow once the collection of Stem cell has been made.
With a recurring revenue base in excess of 75% +, VOS strives to work collaboratively with clients to develop innovative
technology strategies and solutions that address specific business challenges. VOS combines the newest technologies with its
capabilities in distant consulting, Advance Research and Cell therapy design and integration, Franchising and business to meet
the individual needs of patients and with the continuous changes occurring in the diseases grading and presentation and its
treatment.
The Company has its headquarters in Seattle, Washington, and has domestic operations in New Jersey, Pittsburgh. The
Company also has offices in four other countries namely Australia, England, Poland and India. Through its various VOS based
Services platforms, VOS employs 300 professionals providing products, support and counselling to thousands of customers on
six continents across 50+ countries.
VOS’s focus on quality has enabled its development unit in India to be awarded Level 5 status of the University of Pittsburgh
Medical Center’s Capability. The Company has received numerous awards and recognition from its Healthcare industry, the
media, and by customers including being ranked very high in the top 100 fastest growing companies in the world
5
6. Summary Highlights
Industry Leadership Opportunity by Leveraging VOS’s Strong Market Presence. The U.S. Healthcare market is a highly fragmented
$360
billion industry. VOS’s innovative Adult Stem cell Therapy and its global reach, positions it as a possible leader in the worldwide Regenerative
Medicince markets
.Large, Impressive Client Base for Expansion and Cross-selling. VOS’s outstanding reputation with a large customer base and community
of
healthcare professionals offers tremendous expansion and cross-reffering opportunities to accelerate an already very strong market position
One of the Most Successful Regenerative Medicine Companies in the United States in terms of its consistency of results. VOS healthcare has
achieved consistently growing financial metrics for revenues, profits, margins, etc. With a fully post-split diluted EPS of $0.41 for the Q3 of 2011 as
compared to $0.43 in the Q3 of 2010 and $1.51 for the year 2010, VOS has set a very high benchmark for itself. The full year cumulative diluted EPS
for 2010 grew by 47% as
compared to cumulative diluted EPS of $1.03 for the year 2009.
High Growth and Profitable Recurring Revenue Model. With over 75% of its revenue generated from recurring sources, derived from a 99%
plus customer retention rate, VOS has a solid revenue base to build upon affording a high degree of visibility to its growth and future revenues. With
2010 2009 2008 2010 2009 2008
35% revenue 2010 2009 2008 2007 Operating 41% 2009 2008
30% 2007 23% 2006
2010 2009 2008
Margins
growth in 2010 and net income growth of 52% on a year-over-year basis, VOS has continued to post record-setting numbers in terms of income and
Operating Margins 41% 30% 23%
EPS 2011 Q3 Q2 Q1 Q42010
Net income in thousand 42 9 1
$ Consistency of Performance over the last many years. Operating Margins 42% 44% 39% 39%
Growth of 2010 over 52% 116% 365%
other years
Diluted EPS in $ 1.52 1.03 0.36
Q3 2011 Q2 2011 Q1 2011 Q4 2010
Growth of 2010 over 39% 99% 278%
other years
(Diluted earnings per share reflects the 3-for-1 stock split effective January 5, 2010)
6
7. Summary Highlights
Unique Differentiation Enhances VOS Healthcare’s Leadership Opportunity
VOS Healthcare’s exchanges power transactions between hundreds of thousands of patients for these services of stem
cell banking and therapy.
VOS Healthcare’s services extends close to 0.15 million patients every year. VOS Healthcare’s revenue turnaround sums in excess of
$0.5 million in the United States along with overseas business. In Australia the majority of VOS Healthcare work focuses on the Stem
cell Therapy especially on diabetes and cancer treatment. VOS Healthcare’s on-demand Menstrual and Adipose Banking used by
100,000 plus users around the world. With the aggregation of a large community of Stem Cell banking and therapeutics , VOS
Healthcare is seen as a Mentor to Stem Cell markets by these entities. Many Countries are still out of reach of VOS Healthcare
Regenerative Medicine services , gives us a chance to expand and work harder to reach every corner of the globe.
VOS Healthcare has a global reach in Regenerative Medicine knowledge.
VOS Healthcare powers businesses in more than 50 countries today across six continents. VOS Healthcare has a global footprint with
in excess of 10+ offices today world-wide.
VOS Healthcare provides a multi-layer centers(Bud and Root collection center)and advanced lab and research labs with
world-wide quick co-ordination and support, unlike any other player in the regenerative industry that addresses these
markets.
VOS Healthcare systems are multi-lingual, multi-currency and work in French, Portuguese, Spanish, Japanese, Chinese and English.
With fully owned offshore facilities in India, VOS Healthcare has the ability to reduce the cost structure of acquired
companies and increase their efficiency.
VOS Healthcare’s centers in India have Carnegie Mellon’s highest CMMI 5 rating and that establishes the quality of VOS Healthcare’s
operations to any of its prospective customers
Experienced Executive Management Team with Health Expertise and Industry Recognition.
VOS Healthcare’s team includes Physicians, Physician Research, Biotechnologists, Biologist, Nurses and Other accessories Staff with a
deep understanding of the Regenerative Medicine spanning an ample of years of experience amongst them. Its infrastructure and
experienced executive management team is highly capable of sustaining its leadership and developing VOS Healthcare into an even
larger organization.
7
8. Global Footprint
Our markets and our clients cross geographic boundaries. VOS employs hundreds of insurance & technology professionals providin
products, support and consultancy to thousands of customers on six continents across 50+ countries through 30+ offices.
8
10. The Turnaround
! In 2007 VOS Healthcare had $12 Thousand in Net Losses.
! In 2010 VOS had $42.0 Thousand of Net Income.
$42.00
$9.00
$1.00
2010
10
11. Recurring Revenue Streams with
Consistent Growth and Profitability
! 28% revenue growth in Q3 of 2011 as compared to Q3 of 2010 $92.84
! 35% annual revenue growth in 2010 as compared to 2009, 77% as compared to
2008 and 209% as compared to 2007.
! Long-term client relationships with 99.5% retention rates
! Stable, predictable base of recurring revenues
45%
! Approximately 75% plus in recurring revenue streams
! Scaling on-demand model of 40% operating margin levels in 2010
! 52% annual net income growth in 2010 as compared to 2009, 116% as
compared to 2008, 365% as compared to 2007.
$42.84
$24.10
$9.25
$3.75
Revenue Growth & Net Margins (after taxes)
11
12. Recurring Revenue Streams with
Consistent Growth and Profitability
The net income at the end of 2010 grew to $ 42.3 thousand as compared to cumulative net
income of $ 9.4 Thousand at the end of 2009
$1.51
*Diluted earnings per share reflects two 3-for-1
stock splits, namely the 3-for-1 stock split
effective October 9, 2008 and the 3-for-1
stock split effective January 5, 2010
$88.8
2.08
$42.3
$9.4 1.56
$1.3
0.4 1.03
$0.15 $0.21
VOS Net Income Growth & Diluted EPS*
12 A
13. Operating Income and
Operating Cash Flow
Operating Income Quickly grew Realized through Cash Flows
$52.507
Combined Operating Income from 2008-2010 = $0.1 Million
Combined Operating Cash Flows from 2008-2010 = $.4 Million
Realized Operating Cash Flow over 3 yrs. = 300%
$52.779
Operating Income (in thousands)
$39.256
Operating cash flows (in thousands)
$33.877
$12.801
$6.712
$15.039
$4.375
200 2008 2009 2010
7
13
14. Operating Cash Flow
Operating Cash Flow used for:
! Support Organic Growth
! Finance Business Acquisitions $52.779
$51.933
! Re-payment of Debt
! Re-purchase Shares of Common Stock
Operating cash flow (in thousands)
$33.877
$15.039
$4.375
200 2008 2009 2010 YTD 2011
7
14
15. Recurring Income Streams with
Consistent Growth in Margins
Net Income (in millions) $22.30
Operating Margins
$16.70 $16.50
$15.90 $15.20
$14.00
$12.40
44%
42%
40% 40% 39%
39% 39%
Q1-10 Q2-10 Q3-10 Q4-10 Q1-11 Q2-11 Q3-11
VOS Operating Margins & Net Income Growth
15
16. Balance Sheet Metrics
Healthy Balance Sheet with Improving Metrics & Liquidity
Q3 2011 2010 2009 2008
Current Ratio 1.08 1.56 0.62 0.47
Cash Balance (in thousands) $13.941 $23.397 $19.227 $9.475
Working Capital (in thousands) $3.891 $21.697 $(28.582) $(28.330)
Debt/TTM EBITDA 0.35 0.52 0.96 1.53
Debt to equity ratio 0.09 0.15 0.31 0.75
16
17. Balance Sheet
$35.3
Debt $27.2
Dec 31, 2010 - $35.3
Sept 30, 2011 - $27.2
As of As of
Dec 31 2010 Sept 30 2011
2011 Uses of Cash
Share buybacks - $62.7
Extinguishment of Convertible Debt - $6.8
($ in Thousands)
17
19. On-Demand Stem Cell Therapy
Industry & Market Overview
Retrieval center
Differentiating Lab
Stem cell Banking Retrieval center Cell culturing
Franchise center Cell preservations
Umbilical cord banking
Sterile collections Cryotherapy
Enrollment
Packaging Sterilization
Collection
Home collections kits Segregation
Processing
Bar-coded labeling Storing
Preservation
Courier Recombinant genetics
Menstrual blood banking
Centrifuging Restructuring
VOS’s footprint addresses Differentiation
Culturing and growing
many of the most strategic requirements
of the Adult
Disease treatment Stem cell therapy industry
Diabetes Research Lab
Liver diseases Global Services Canada
Cardiovascular disorders United states of America
Bone disorder United states of America United Kingdom
Cancer United kingdom Germany
Neuromuscular diseases Poland Poland
Lung disease India Japan
Erectile dysfunction Australia India ( on going)
Anti-ageing & cosmetics
19
27. DR Tapan Shah
CEO, VOS Healthcare LLC,
MS, DNB, FaCS, FRCS, MRCP, PhD
Dr.Tapan Shah is founder and CEO of VOS Healthcare LLC, USA, the leading
Regenerative Medicine & Stem Cell Industry on STEM CELL Therapy with a
view to provide the services across Asia Pacific and Europe.
He brings more than 15 years of experience from the Healthcare industry, and
has served in various positions, focusing especially on global marketing and
branding strategy; brand/ product advertising; and corporate communications
Prior to establishing VOS Healthcare LLC, USA, he was Vice President of ReeCell for Ebix Inc, a world
leader in Bioengineering and Biopharma and biotechnology. Based in USA, he being a Liver and
Pancreatic Transplant surgeon along with his dedication towards regenerative medicine, he developed a
core initiation to develop a medical stream to bring disease free world and a cure to all the diseases.
Dr.Tapan Shah was also an account director for ten years with two global healthcare business
Worldwide, where he directed many successful transplant and regenerative programs.
Dr.Tapan Shah is dedicated to sharing his experience with the international audience. He regularly
accepts invitation to chair and speak in top-notched events across Asia and Europe. Recently, he was
appointed chairman of REGER MED2009. He contributes leadership opinion articles on ORGAN
TRANSPLANTATION AND REGENERATIVE MEDICINE issues to international publications.
He is Visiting Professor in Liver Transplantation and Stem cell Center at the UNIVERSITY OF
DRESDEN, GERMANY.
28. Sudha shah
President and CEO, VOS Healthcare Pvt Ltd
Sudha shah is the founding partner, Chief Executive Officer of VOS Healthcare
LLC. VOS provides REGENERATIVE MEDICINE & STEM CELL BANKING and it’s the
only provider for INTERNATIONALLY ACCEPTED stem cell treatment and Banking
not only CORD BLOOD but also Menstrual blood, Adipose Tissues. VOS’ team of
architects and application experts continue to solve complex infrastructure
challenges, helping customers navigate through the convergence of services,
treatment, banking and counseling.
Ms. Shah is responsible for expanding VOS' leadership position in the industry and provides
strategic direction and business development expertise. With a prestigious list of more than
100000 customers and with products deployed all over the globe extending from North America to
Australia, VOS prides itself in understanding and addressing ongoing challenges for its customers by
staying ahead of the technology curve.
She has more than 10 years of Hospital Administration related experience, including strategic
business development, marketing, and product management, bioengineering and patient care and
counseling along with sales for domestic and international markets. Ms. Shah earned lots
of patents during her tenure at Cisco (formerly known as Scientific Atlanta).
She holds a Masters of Commerce degree from The M.S University of Vadodara, Gujarat, India
and a Master of Business Administration Specialization in Hospital Administration from M. S
University.
29. Suresh Nair Profile
Born: March 7, 1976
Achievement: One of the founders of VOS HEALTHCARE LLC, USA;
Suresh Nair is the Non-Executive Chairman and Chief Mentor of VOS
HEALTHCARE LLC. He is an
epitome of the fact that honesty, transparency, and moral integrity are
not at variance with business acumen. He set new standards in corporate
governance and morality.
Born on March 7, 1976, N.R. Suresh Nair is a B.E. Electrical from University of
Vallabh Vidhyanagar and M B A from M.S. University (1969). Suresh Nair began
his career with TCS in Mumbai and later went to Seattle, WA. Later with his
vision for future developed his own company SURAN LLC, USA in Seattle WA. In
2007, Suresh Nair founded VOS HEALTHCARE LLC with two other professionals.
In 2010, VOS HEALTHCARE LLC opened many international office in Poland, UK,
India, Australia.
Along with the growth of VOS Healthcare LLC, USA, Suresh Nair too has grown
in stature. He has received many honours and awards.
30. New Growth Initiatives
Phase I Phase II
Developing Root Developing bud
Labs centers (
franchise)
Phase III
Phase IV
Developing Full
Developing
fledged Lab
Research Lab
31. New Growth Initiatives
Differentiation Labs
INTERFACED
On-Demand
Franchise Stem Cell
Bud collection Therapy Patient Care Executive
INTERFACED INTERFACED
Root collection
INTERFACED
Associated research lab
! Used by BUD Collection center , ROOT Collection center, Review and Ethical Committee, Differentiating Lab, Research Lab
Patient care Executive, Physicians and Social workers, courier, Stem cell Banks
31
33. Adult Stem Cell Therapy- Diabetes
Diabetes affects 25.8 million people of all ages
8.3 percent of the U.S. population
•Among U.S. residents ages 65 years and older, 10.9 million, or 26.9 percent, had
diabetes in 2010.
•About 215,000 people younger than 20 years had diabetes—type 1 or type 2—in the
United States in 2010.
•About 1.9 million people ages 20 years or older were newly diagnosed with diabetes in
2010 in the United States.
•In 2005–2008, based on fasting glucose or hemoglobin A1C (A1C) levels, 35 percent of
U.S. adults ages 20 years or older had pre-diabetes—50 percent of adults ages 65 years
or older.
•U.S. population in 2010 yields an estimated 79 million American adults ages 20 years or
older with pre-diabetes.
•Diabetes is the leading cause of kidney failure, nontraumatic lower-limb
amputations, and new cases of blindness among adults in the United States.
•Diabetes is a major cause of heart disease and stroke.
•Diabetes is the seventh leading cause of death in the United States.
34. Adult Stem Cell Therapy- Liver Disease
•The prevalence of ALD is estimated at >8.4 million people.
•Liver Diseases is the foremost health risk in developing
countries and ranks third in developed countries.
•Liver Diseases caused by ALD, Hepatitis C & B, Other causes
•Only treatment for liver diseases were LIVER
TRANSPLANTATION
•Liver Transplantation is not only very cost but available at very
few centers
•Liver Transplantation is not always possible due to non
availability of organ
35. Adult Stem Cell Therapy-Heart Disease
• 33.5 percent of adults 20 years and older in America have high
blood pressure; 80 percent are aware of their condition but less
than half have their condition under control.
•23.1 percent of men and 18.1 percent of women are cigarette
smokers; 19.5 percent of students in grades 9 through 12 report
current tobacco use.
•15 percent of adults 20 and older have total serum cholesterol
levels of 240 mg/dL or higher.
•8 percent of adults have been diagnosed with diabetes mellitus;
36.8 percent have prediabetes.
•More than 67 percent of adults are overweight.
•During the past 30 years, the prevalence of obesity in children 6
to 11 years has increased from about 4 percent to more than 20
percent
36. Adult Stem Cell Therapy-Cancer
•Cancer rates could further increase by 50% to 15 million new
cases in the year 2020
•malignant tumours were responsible for 12 per cent of the
nearly 56 million deaths worldwide
•The World Cancer Report tells us that cancer rates are set to
increase at an alarming rate globally
• from 10 million new cases globally in 2000, to 15 million in 2020
•About 60 per cent of cases occur in developing countries, with
the highest incidence rates coming in Eastern Asia
37. Adult Stem Cell Therapy- Neurology
•Currently 30 million people with dementia in the world
•13.9% of people aged 71+ are affected by dementia
•Nearly half of people aged 85 and older (43 percent) have Alzheimer’s Disease
•An estimated 5.4 million people have Alzheimer’s disease in USA
•4.6 million new cases annually ( one new case very 7 second)
•Over 100 million people would be affected by 2050
•14.9 million unpaid caregiver
•183 billion dollars in annual costs
•1 in 8 older Americans have ALZHEIMER DISEASE
Prevalence of Parkinson's Disease: 21 million people
Prevalence Rate: approx 1 in 272 or 0.37% or 1 million people
Undiagnosed prevalence of Parkinson's Disease: estimated 3-4 million people
Undiagnosed prevalence rate: approx 1 in 90 or 1.10% or 3 million people
Death rate extrapolations for Parkinson's Disease: 14,593 per year, 1,216 per
month, 280 per week, 39 per day, 1 per hour
38. Adult Stem Cell Therapy- Ortho/ Knee
•13.9% of adults aged 25 + and 33.6% (12.4 million) of those 65+
has OsteoArthritis
•An estimated 41.9 million US adults in 2011 has OA
•Incidence rates increased with age, and level off around age 80.
•Women had higher rates than men, especially after age 50
•$25.9 billion estimated costs of knee and hip replacements in 2011
•Average direct costs of OA ~$9,600 per year out-of-pocket
expenses.
•OA of the knee is 1 of 5 leading causes of disability among non-
institutionalized adults
•80% of patients with OA have some degree of movement
limitation
•25% cannot perform major activities of daily living (ADL’s)
• About 40% of adults with knee OA reported their health “poor”
39. 7 billion customers needs us
• 7 billion
Population • 1 billion Indians
• 1 out of 6 has lethal diseases
Diseases • 1 out of 3 has morbid or lethal diseases
• 1 out of 3 needs stem cell therapy
Stem cell
• If cosmetic/anti-aging included all needs stem
therapy cell therapy
40. New Growth Initiatives - Exchange
FRANCHISE : BUD collection centers
VOS HEALTHCARE ( NaSCFI) Labs is introducing a program by which satellite labs are built in foreign
sites. VOS HEALTHCARE ( NaSCFI) has been producing two types of stem cells from discarded human
umbilical cords(cord blood) AND Adult Stem cells ( adipose, menstrual, neural). These cells have
proven, in international as well as our own experience, to be quite effective and safe in a number of
different health conditions. VOS HEALTHCARE ( NaSCFI) also realizes that having laboratories in
individual states and countries would increase their availability, help more people, avoid the problems
of transportation and importation of such sensitive live cells. In particular, keeping the cells within the
bounds of one state removes jurisdiction from Federal agencies, such as the Food and Drug
Administration and the Federal Trade Commission.
Some desire to establish a stem cell treatment center, as well as the production lab. One lab could
supply many treatment centers. Our intention is to provide labs in individual states, on a first-
come, first-served basis, so that there will not be excessive competition for the existing market. We will
continue a system-wide marketing program, which will provide demand for the product.
Research-level labs will also be available, for an additional cost. These may also be financed by the
same organization. We will have one research lab for each ten production labs. Production labs would
partially support the research labs, and intellectual property would be shared throughout the system.
The above price does not include: full research lab capabilities, vehicles, income or other taxes, back-
up power, or real estate, but does include several months rent or real-estate payments. Real-estate can
also be financed.
Franchisee obligations include assistance with hiring, licensing, coordination with local medical
personnel, including at least one licensed physician to order supplies, procuring a contract for
cords, and local marketing. Franchisee will also provide a 10% licensing fee for each stem cell unit sold.
Lab is designed to fit in a 700 ft2 office or lab space
Projected profits operating at a low level (2 cords per day) would yield over $1 million yearly, and
expansion up to 8 cords per day ($5 M per year) could be done with this lab.
32
41. New Growth Initiatives
Stem Cell Banking
Fixed deposit of health
Premium of life insurance
Pension your Health Guard
Stem cell Banking
Cord blood banking Other Stem cell banking
•A Menstrual blood stem cell
•cGTP & c GMP accredited labs •first of its kind in India with international standard
•Precious gift given to every new born •normally discarded as unsanitary waste, is now a boon
•properties and characteristics similar to both bone marrow and
•Cord and placental banking possible embryonic stem cells.
•Collections network all across gynec hospitals •easily collected with painless and non-invasive procedures
•Highest sterility techniques ( rated best) •processed and harvested at affordable rates.
•Easily collected and handled Adipose stem cell banking
•Helps treating many early age diseases •Adipose (fat) tissue is found throughout body.
•ability to differentiate into bone, muscle, fat, nerve, and cartilage.
•Higher viable stem cell •obtain through a simple and localized liposuction process
•Banking near airport, so quick response •Adipose-derived stem cells are easy to obtain thro liposuction
•same morphology, immune phenotype and differentiation capacity
•free of ethical debate /abundant and easy to access.
•yield more than 200 million stem cells of which 95% are mesenchymal
stem cells.
•cryopreservation: for almost 25 years
34
42. VOS’s Revenue Drivers - Exchange
Advance labs and Regenerative Medicine 2010 - 12% Q3 2011 - 8%
Percentage of Total Revenue
•Advance lab
•Culturing
•Sterilization
•Cell counting
•Stimulation
Advance labs and
•Cyro preservation
Research labs
•Differentiation and growth
•Newer source of stem cell
•Newer means of delivering
•Local patches and oral delivery
•Biopharma
•More viability and efficacy
35
43. VOS’s Revenue Drivers
The healthcare Channel 2010 - 10% Q3 2011 - 11%
Percentage of Total Revenue
•Self manageable kits •Coordination with patients and bud centers
•Adequate education •Cohesively work with root centers
•Door step collection and counselling •Patient counseling
•Online consultation
•No OPD policy •Marketing and media conferencing
•Mass awareness activity •Corporate liaisioning
•24*7 helpline •Packaging and Culturing
•Ethical committee
•Review committee •Achieves handling
•Finance availability •Labeling and forwarding
•Special package for corporate Patients Center
groups
Lab
BUD collection center
Root collection center
Advance lab
Research lab
37
44. Acquisitions
!Marketplace remains robust
!Constantly evaluating companies
!Prices coming down
Criteria
!Accretive to earnings in 90-180 days
!Adds to our Customer base
!Adds to our Product base
!70% or more of recurring revenue
!Service On-Demand a must
!Low customer attrition rates
!Complements our existing product base
38
45. Understanding of Competitive Edge
The Secret Mantra
Cost Price Selling Price
Key Company Goals: Operating Margins of 40% or more
On Demand Banking and Franchise generating revenue str
39
46. Summary
! First mover advantage in our markets
! Large untapped market potential
! Minimal customer attrition
!75% plus recurring revenues
! Sustainable 40% operating margins
! Strong free cash flow generation
! Minimal debt
! Chairman owns 20% of the company
40